Prosecution Insights
Last updated: July 17, 2026

Haug Partners LLP

35 pending office actions • 19 clients • 34 examiners • 25 art units • 0 of 35 (0%) have an AI response strategy ready • 33 patents granted in the last 365 days

Quality Metrics (n=15994 apps, methodology: how we score firms)

83.0%
Allowance Rate
n=15994
+0.56σ
Allowance Rate (norm)
n=15994
3.8
OAs to Allowance
n=11527
+0.18σ
OAs to Allow (norm)
n=11527
1323 days
Time to Allowance
n=11527
+4.5pp
Interview Lift
n=15994
29.6%
RCE Rate
n=15994
1.7%
Appeal Rate
n=15994

Rejection Performance (% of received rejections ultimately overcome)

86.9%
§101 Overcome
n=314
85.0%
§102 Overcome
n=1668
82.9%
§103 Overcome
n=6034
88.9%
§112 Overcome
n=1105

Specialization & Scale

H04N, G06F, A61K
Top CPC Subclasses
17%
Top-3 CPC Share
n=15994
31
Practitioners
n=15994
515.9
Apps / Practitioner
n=15994

Portfolio Summary

35
Total Pending OAs
18
Non-Final OAs
15
Final Rejections
2
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 22 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

14
Overdue
0
Due this week
5
Due this month
3
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 22 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (14)Due ≤ 30 days (5)Due ≤ 60 days (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (6%)
22
Medium (63%)
9
Easy (26%)
2
Unknown (6%)

Rejection Statute Mix

BucketCases
§101 only2 (6%)
§103 only18 (51%)
§102 only4 (11%)
§112 only6 (17%)
Double-patenting only3 (9%)
No statute on record2 (6%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

16
Life Sciences
46% of docket
1
Information Tech
3% of docket
1
Communications
3% of docket
0
Semiconductors
0% of docket
14
Mechanical / Eng
40% of docket
3
Business / Other
9% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

350 h
Manual time on pending OAs
70 h
Time saved (low, 20%)
122 h
Time saved (mid, 35%)
3.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PEFFLEY, MICHAEL F 2 77.6% +12.9%
UPCHURCH, DAVID M 1 73.6% +17.9%
ABDOSH, SAMIR 1 83.9% +6.4%
HOLLOMAN, NANNETTE 1 60.7% +22.9%
ELDRED, JOHN W 1 77.6% +7.9%
KOBYLARZ, ANDREW M 1 76.7% +19.9%
SHAKERI, HADI 1 62.1% +37.2%
GUILLERMETY, JUAN M 1 72.4% +14.3%
SCHWARZENBERG, PAUL 1 61.9% +28.5%
DANIEL JR, WILLIE J 1 60.9% +20.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
19115175 FINGER SUPPORT THAT CAN BE ATTACHED TO AND REMOVED FROM FIREARMS ABDOSH, SAMIR 18d overdue

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18679327 FINANCIAL TRANSACTION FRAUD PREVENTION SYSTEM USING HYSTERESIS MODELS, DECISION TREES, AND TRANSFORMER NETWORKS SCHWARZENBERG, PAUL 33d
16095563 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS CHEONG, CHEOM-GIL

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18739123 PRINTING FROM A HANDHELD DEVICE VIA A REMOTE SERVER GUILLERMETY, JUAN M 88d overdue
18131759 BLADDER TISSUE MODIFICATION FOR OVERACTIVE BLADDER DISORDERS PEFFLEY, MICHAEL F 52d overdue
18571421 Method and apparatus for wireless synchronization of mobile devices DANIEL JR, WILLIE J 38d overdue
18956263 SPACER FOR RESISTANCE ADJUSTMENT IN RESISTANCE TRAINING APPARATUS KOBYLARZ, ANDREW M 19d
17990634 DEVICES AND METHODS FOR TRANSURETHRAL BLADDER PARTITIONING PEFFLEY, MICHAEL F 20d
18679327 FINANCIAL TRANSACTION FRAUD PREVENTION SYSTEM USING HYSTERESIS MODELS, DECISION TREES, AND TRANSFORMER NETWORKS SCHWARZENBERG, PAUL 33d
19120187 A MULTI-PURPOSE TACTICAL UNIFORM LOCK THAT IS EASILY ATTACHED AND DETACHED UPCHURCH, DAVID M
19064180 METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS HOLLOMAN, NANNETTE

Client Portfolio (19 clients)

Top Art Units

Art UnitApps
37943
36412
16232
16452
37832
16412
16112
36771
37841
26821

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19120187 A MULTI-PURPOSE TACTICAL UNIFORM LOCK THAT IS EASILY ATTACHED AND DETACHED Samsun Yurt Savunma Sanayi Ve Ticaret Anonim Sirketi UPCHURCH, DAVID M 3677 §102 Non-Final OA Pending Apr 10, 2025
19115175 FINGER SUPPORT THAT CAN BE ATTACHED TO AND REMOVED FROM FIREARMS Samsun Yurt Savunma Sanayi Ve Ticaret Anonim Sirketi ABDOSH, SAMIR 3641 §102 Non-Final OA 18d overdue Pending Mar 25, 2025
19064180 METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS Respira Therapeutics, Inc. HOLLOMAN, NANNETTE DP Non-Final OA Pending Feb 26, 2025
18869920 A GRIP DESIGN WITH AN INSERT MANUFACTURED IN ONE PIECE BY INJECTION Samsun Yurt Savunma Sanayi Ve Ticaret Anonim Sirketi ELDRED, JOHN W 3641 §103 Final Rejection 8d Pending Nov 27, 2024
18956263 SPACER FOR RESISTANCE ADJUSTMENT IN RESISTANCE TRAINING APPARATUS Harambe System LLC KOBYLARZ, ANDREW M 3784 §103 Non-Final OA 19d Pending Nov 22, 2024
18838985 GUN-SHAPED SCREWING APPARATUS WHICH COMPRISES A TOOLBOX WITHIN AND WHICH CAN BE USED FOR THE ASSEMBLY OF FIREARM ACCESORIES Samsun Yurt Savunma Sanayi Ve Ticaret Anonim Sirketi SHAKERI, HADI §103 Non-Final OA Pending Aug 15, 2024
18739123 PRINTING FROM A HANDHELD DEVICE VIA A REMOTE SERVER Quest Diagnostics Investments LLC GUILLERMETY, JUAN M 2682 §103 Non-Final OA 88d overdue Pending Jun 10, 2024
18679327 FINANCIAL TRANSACTION FRAUD PREVENTION SYSTEM USING HYSTERESIS MODELS, DECISION TREES, AND TRANSFORMER NETWORKS Givecorporation, Inc. SCHWARZENBERG, PAUL 3695 §101 Final Rejection 33d Pending May 30, 2024
18571421 Method and apparatus for wireless synchronization of mobile devices Sennheiser Electronic SE & Co. Kg DANIEL JR, WILLIE J 2465 §102 Non-Final OA 38d overdue Pending Dec 18, 2023
18568249 MACROCYCLIC TAK1 INHIBITORS Aqilion AB LEE, WILLIAM Y 1623 §112 Non-Final OA Pending Dec 07, 2023
18287096 FORMULATIONS OF CANNABINOIDS Add Advanced Drug Delivery Technologies Ltd. CHONG, YONG SOO 1623 §103 Final Rejection 52d overdue Pending Oct 16, 2023
18275351 METHOD FOR DETERMINING WHETHER A SUBJECT IS AT RISK OF DYING FROM BREAST CANCER OR PROSTATE CANCER Nightingale Health Oyj WECKER, JENNIFER 1797 §103 Non-Final OA 42d Pending Aug 01, 2023
18338805 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS 4TEEN4 Pharmaceuticals GmbH KARUNASENA, ENUSHA 1645 DP Non-Final OA Pending Jun 21, 2023
18198228 Method and Apparatus for Storing Energy King Saud University NASSER, ROBERT L 3992 §112 Non-Final OA 50d Pending May 16, 2023
18036733 METHOD FOR ASSISTING DETERMINATION ON SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, METHOD FOR DETERMINING SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, METHOD FOR COLLECTING DATA FOR USE IN DETERMINATION ON SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, METHOD FOR DIAGNOSING SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, IN VITRO METHOD FOR ASSISTING DETERMINATION ON SUITABILITY OF ESOPHAGEAL CANCER FOR ENDOSCOPIC THERAPY, ... Public University Corporation Nagoya City University BUCHANAN, BAILEY CHEYENNE 1682 §102 Final Rejection Pending May 12, 2023
18131759 BLADDER TISSUE MODIFICATION FOR OVERACTIVE BLADDER DISORDERS Newuro, B.V. PEFFLEY, MICHAEL F 3794 §103 Final Rejection 52d overdue Pending Apr 06, 2023
18027883 CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS TriSalus Life Sciences, Inc. POLIAKOVA-GEORGAN, EKATERINA 1637 §103 Final Rejection 32d overdue Pending Mar 22, 2023
18027895 CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS TriSalus Life Sciences, Inc. WHITEMAN, BRIAN A 1636 §103 Non-Final OA 21d Pending Mar 22, 2023
18087767 SYSTEMS AND METHODS FOR CONTROLLING FLOW OF THERAPEUTIC AGENT DELIVERED TO AN INFUSION CATHETER TriSalus Life Sciences, Inc. PATEL, SHEFALI DILIP 3783 §112 Non-Final OA 28d Pending Dec 22, 2022
18087508 SYSTEMS AND METHODS FOR SELECTIVELY INDUCING VASOCONSTRICTION TO INCREASE THERAPEUTIC UPTAKE IN TISSUE TriSalus Life Sciences, Inc. JIAN, SHIRLEY XUEYING 3792 §103 Non-Final OA Pending Dec 22, 2022
18011082 METHOD FOR DETERMINING WHETHER A SUBJECT HAS A DISEASE OR CONDITION OR IS AT RISK OF DEVELOPING A DISEASE OR CONDITION Nightingale Health Oyj FRITCHMAN, REBECCA M 1758 §112 Non-Final OA 9d overdue Pending Dec 16, 2022
17992433 THERAPEUTIC TREATMENT DEVICE WITH BRAIDED-STRAND MICROVALVE OCCLUDER HAVING MODIFIED FILTER COATING TriSalus Life Sciences, Inc. HOUSTON, ELIZABETH 3771 §103 Final Rejection Pending Nov 22, 2022
17990634 DEVICES AND METHODS FOR TRANSURETHRAL BLADDER PARTITIONING Newuro, B.V. PEFFLEY, MICHAEL F 3794 §103 Final Rejection 20d Pending Nov 18, 2022
17984611 DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS 4TEEN4 Pharmaceuticals GmbH WEN, SHARON X 1641 Other Non-Final OA 45d overdue Pending Nov 10, 2022
17953152 DEVICES AND METHOD FOR FAR FIELD BIPOLAR ABLATION Newuro, B.V. SHOULDERS, ANNIE LEE 3794 §103 Final Rejection 4d overdue Pending Sep 26, 2022
17802799 DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK 4TEEN4 Pharmaceuticals GmbH AEDER, SEAN E 1642 §112 Non-Final OA Pending Aug 26, 2022
17602356 PROCESS FOR CONTINUOUS PRODUCTION OF AN ACTIVE INGREDIENT GRANULATE Add Advanced Drug Delivery Technologies Ltd. JANOSKO, CHASITY PAIGE 1613 §103 Final Rejection 23d overdue Pending May 25, 2022
17769398 CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES Add Advanced Drug Delivery Technologies Ltd. BAEK, BONG-SOOK 1611 §103 Final Rejection 67d overdue Pending Apr 15, 2022
17637518 THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK 4TEEN4 Pharmaceuticals GmbH TAYLOR, LIA ELAN 1641 DP Final Rejection Pending Feb 23, 2022
17622187 DIGITAL CERTIFICATE PROCESSING METHOD, GATEWAY, DEVICE, SYSTEM, MEDIUM, AND PROGRAM PRODUCT Antpool Technologies Limited QAYYUM, ZESHAN 3697 §112 Final Rejection Pending Dec 22, 2021
17557132 THERAPEUTIC PILLOW Invicta Watch Company Of America, Inc. SUN, GEORGE 3673 §103 Non-Final OA 98d overdue Pending Dec 21, 2021
17610127 METHODS AND SYSTEMS FOR PROTEIN ENGINEERING AND PRODUCTION Labgenius Ltd. PLAYER, ROBERT AUSTIN 1686 §103 Final Rejection Pending Nov 09, 2021
17236446 Atraumatic Occlusive System with Compartment for Measurement of Vascular Pressure Change TriSalus Life Sciences, Inc. MEDWAY, SCOTT J 3783 §103 Non-Final OA 11d overdue Pending Apr 21, 2021
16513238 MULTIPARTICULATE FORMULATIONS OF CANNABINOIDS Glatt GmbH ALAM, AYAAN A 1611 Other Non-Final OA 45d overdue Pending Jul 16, 2019
16095563 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS 4TEEN4 Pharmaceuticals GmbH CHEONG, CHEOM-GIL 1645 §101 Final Rejection Pending Oct 22, 2018

Managing Haug Partners LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month